The SARS CoV 2 mortality and co-morbidities A narrative review

Abstract

Background :

The SARS CoV 2 patients who appear with existing co-morbidities may have a greater chance of decline and require admission in the ICU for close monitoring according to the World Health Organization guideline for well management. The ability to assess the comorbidities fuse with bad prognosis among SARS CoV 2 infected patients is important for early procedures in order to strengthen these patients treatment outcome.

Objective:

• To find out whether comorbidities are associated with higher SARS CoV 2 mortality or not.
• To find out comorbidity with higher mortality

Methods:

In this study we use narrative review approach .We searched Pub Med and Google Scholar data from December 2019 to June 2021. The result of searching was the occurrence of SARS CoV 2 mortality in patients with existing co-morbidities. We analysed twelve co-morbidities: Hypertension, Diabetes, Chronic Kidney Disease (CKD), Obesities, Liver Disease, Heart failure, Asthma, Cancer, HIV, Coronary Artery Disease (CAD), COPD and Cerebrovascular Disease (CVD).

Results:

From nine studies we   analysed   10991 confirm cases of CoVID-19 motality.10991 cases include patients of all ages and both gender. In 10991 confirm CoVID-19 patients; 4094 had hypertension, 2180 had diabetes, 746 had CKD, 83 had asthma, 56 had CAD, 831 had heart failure, 643 had liver disease, 329 had Cancer, 994 had COPD, 354 had obesity, 670 had CVD and 11 had HIV .

 Conclusion:

SARS CoV 2 patients with hypertension, diabetes, CAD, heart failure, CKD, liver disease, asthma, cancer, obesity, HIV, CVD and COPD have a greater chance of mortality compare to   patients having SARS CoV 2 without co-morbidities. If we improve the infection prevention and treatment strategies of co-morbidities in SARS CoV 2 patients it may lead to improve the survival rate and a positive outcome of treatment.